Skip to main content
SpringerLink
Log in

Selection of Primary Breast Cancer Patients for Adjuvant Endocrine Therapy – is Oestrogen Receptor Alone Adequate?

  • Conference Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Among 834 patients who had primary breast cancer treated by surgery without adjuvant systemic therapy, 363 had relapse treated by endocrine therapy alone. Patients with oestrogen receptor positive tumours (median: 70 vs. 45 months, p<0.0001) or with non-progression at 6 months of therapy (median: 111 vs. 37 months, p<0.0001) survived longer than those with oestrogen receptor negative tumours or with disease progression respectively, presumably due to the effect of therapy. On the other hand, the median disease-free interval, uninfluenced by therapy, showed a similar difference: oestrogen receptor positive versus negative=29 versus 21 months, p<0.005; non-progression versus progression=40 versus 19 months, p<0.0001. Patients with oestrogen receptor-positive tumours and non-progression at 6 months had the longest disease-free interval. The present study has established that there are factors, other than the oestrogen receptor, inherent in the primary tumour as reflected by the disease-free interval, which affect hormone sensitivity. Selection of adjuvant endocrine therapy based on the oestrogen receptor alone would deem inadequate. Further studies to elucidate other possible factors are warranted to refine the use of endocrine therapy, especially in the adjuvant setting when no indication of response is available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Walt AJG, Singhakowinta A, Brooks SC, Cortez A: The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery 80: 506-512, 1976

    Google Scholar 

  2. Knight WA, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37: 4669-4671, 1977

    Google Scholar 

  3. Maynard PV, Blamey RW, Elston CW, Haybittle JL, Griffiths K: Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res 38: 4292-4295, 1978

    Google Scholar 

  4. Brooks SC, Saunders DE, Singhakowinta A, Vaitkevicius VK: Relation of tumor content of estrogen and progesterone receptors with response of patient to endocrine therapy. Cancer 46: 2775-2778, 1980

    Google Scholar 

  5. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884-2888, 1980

    Google Scholar 

  6. Croton R, Cooke T, Holt S, George WD, Nicholson RI, Griffiths K: Oestrogen receptors and survival in early breast cancer. Br Med J 283: 1289-1291, 1981

    Google Scholar 

  7. Howell A, Barnes DM, Harland RNL, Redford J, Bramwell VHC, Wilkinson MJS, Swindell R, Crowther D, Sellwood RA: Steroid-hormone receptors in survival after first relapse in breast cancer. Lancet 1: 588-591, 1984

    Google Scholar 

  8. Hawkins RA, White G, Bundred NJ, Dixon JM, Miller WR, Stewart HJ, Forrest ADM: Prognostic significance of oestrogen and progesterone receptor activities in breast cancer. Br J Surg 74: 1009-1913, 1987

    Google Scholar 

  9. Williams MR, Todd JH, Ellis IO, Dowle CS, Haybittle JL, Elston CW, Nicholson RI, Griffiths K, Blamey RW: Oestrogen receptors in primary and advanced breast cancer: An eight year review of 704 cases. Br J Cancer 55: 67-73, 1987

    Google Scholar 

  10. Samaan NA, Buzdar AV, Aldinger KA, Schultz PN, Yang K, Romsdahl MM, Martin R: Estrogen receptor-a prognostic factor in breast cancer. Cancer 47: 554-560, 1981

    Google Scholar 

  11. Allegra JC, Barlock A, Huff KK, Lippman ME: Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 45: 792-794, 1980

    Google Scholar 

  12. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K: A prognostic index in primary breast cancer. Br J Cancer 45: 361-366, 1982

    Google Scholar 

  13. Galea MH, Blamey RW, Elston CW, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: 207-219, 1992

    Google Scholar 

  14. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289-1293, 1977

    Google Scholar 

  15. Nicholson RI, Campbell FC, Blamey RW, Elston CW, George D, Griffiths K: Steroid receptors in early breast cancer: value in prognosis. J Ster Biochem 15: 193, 1981

    Google Scholar 

  16. Robertson JFR, Bates K, Pearson D, Blamey RW, Nicholson RI: Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer 65: 727-730, 1992

    Google Scholar 

  17. British Breast Group: Assessment of response to treatment in advanced breast cancer. Lancet 2: 38-39, 1974

    Google Scholar 

  18. Williams MR, Todd JH, Nicholson RI, Elston CW, Blamey RW, Griffiths K: Survival patterns in hormone treated advanced breast cancer. Br J Surg 73: 752-755, 1986

    Google Scholar 

  19. Robertson JFR, Dixon AR, Nicholson RI, Ellis IO, Elston CW, Blamey RW: Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat 22: 221-227, 1992

    Google Scholar 

  20. Robertson JFR, Williams MR, Todd J, Nicholson RI, Morgan DAL, Blamey RW: Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 25: 469-475, 1989

    Google Scholar 

  21. Cheung KL, Willsher PC, Pinder SE, Ellis IO, Elston CW, Nicholson RI, Blamey RW, Robertson JFR: Predictors of response to second-line endocrine therapy for breast cancer. Breast Cancer Res Treat 45: 219-224, 1997

    Google Scholar 

  22. Robertson JFR, Willsher PC, Cheung KL, Blamey RW: The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 33: 1774-1779, 1997

    Google Scholar 

  23. Cheung KL, Robertson JFR: The importance of stable disease in breast cancer patients treated with endocrine therapy. Breast Cancer Abstracts 1: 2-4, 1999

    Google Scholar 

  24. Charpin C, Martin PM, Jacquemier J, Lavaut MN, Pourreau-Schneider N, Toga M: Estrogen receptor immunocytochemical assay (ER-ICA): computerized image analysis system, immunoelectron microscopy, and comparisons with estradiol binding assays in 115 breast carcinomas. Cancer Res 46 (Suppl): 4271s-4277s, 1986

    Google Scholar 

  25. Jonat W, Maass H, Stegner HE: Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples. Cancer Res 46(Suppl): 4296s-4298s, 1986

    Google Scholar 

  26. Campbell FC, Blamey RW, Elston CW, Nicholson RI, Grif-fiths K, Haybittle JL: Oestrogen-receptor status and sites of metastases in breast cancer. Br J Cancer 44: 456-459, 1981

    Google Scholar 

  27. Stewart JF, King RJ, Sexton SA, Millis RR, Rubens RD, Hayward J: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17: 449-453, 1981

    Google Scholar 

  28. Johnson PA, Bonomi PD, Anderson KM, Wolter JM, Bacon LD, Rossof AH, Economou SG: Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study. Cancer Treat Rep 67: 717-720, 1983

    Google Scholar 

  29. Bonomi P, Johnson P, Anderson K, Wolter J, Bunting N, Strauss A, Roseman D, Shorey W, Economou S: Primary hormone therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels. Semin Oncol 12 (1 Suppl 1): 48-54, 1985

    Google Scholar 

  30. Borg A, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Olsson H, Killander D, McGurie WL: Association of INT2/HST1 coamplification in primary breast cancer with hormonedependent phenotype and poor prognosis. Br J Cancer 63: 136-142, 1991

    Google Scholar 

  31. Hui R, Cornish AL, McClelland RA, Robertson JFR, Blamey RW, Musgrove EA, Nicholson RI, Sutherland RL: Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res 2: 923-928, 1996

    Google Scholar 

  32. Watts CKW, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL: Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 9: 1804-1813, 1995

    Google Scholar 

  33. Hui R, Ball JR, Macmillan RD, Kenny FS, Prall OW, Campbell DH, Cornish AL, McClelland RA, Daly RJ, Forbes JF, Blamey RW, Musgrove EA, Robertson JFR, Nicholson RI, Sutherland RL: EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 17: 1053-1059, 1998

    Google Scholar 

  34. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987

    Google Scholar 

  35. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220-1226, 1999

    Google Scholar 

  36. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S: C-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary node metastases. J Clin Oncol 14: 2702-2708, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Professorial Unit of Surgery, City Hospital, Nottingham, UK

    K.L. Cheung, R.W. Blamey & J.F.R. Robertson

  2. Tenovus Cancer Research Centre, Cardiff, UK

    R.I. Nicholson

Authors
  1. K.L. Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R.I. Nicholson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R.W. Blamey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J.F.R. Robertson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cheung, K., Nicholson, R., Blamey, R. et al. Selection of Primary Breast Cancer Patients for Adjuvant Endocrine Therapy – is Oestrogen Receptor Alone Adequate?. Breast Cancer Res Treat 65, 155–162 (2001). https://doi.org/10.1023/A:1006430401243

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006430401243

Search

Navigation